- Idenix Pharmaceuticals (IDIX) starts patient enrollment in HELIX-2 — that's the DAA HCV combo comprising samatasvir and the JNJ co-developed protease inhibitor and polymerase inhibitor simeprevir and TMC647055.
- The Phase 2 study will evaluate efficacy, safety and tolerability of the combo in treatment-naïve or relapsed (after interferon and ribavirin) GT1 HCV patients. (PR)
- In other company news, IDIX has filed two patent infringement lawsuits against Gilead (GILD) tied to methods of treating the HCV using 2'-methyl nucleosides.
- Here's IDIX: "[The company] is seeking a declaration that GILD's imminent distribution, importation, use, sale or offer to sell drugs containing sofosbuvir, a 2'-methyl nucleoside compound, infringes IDIX's patents." (PR)